SMALL CELL LUNG CANCER EXTENSIVE STAGE
Clinical trials for SMALL CELL LUNG CANCER EXTENSIVE STAGE explained in plain language.
Never miss a new study
Get alerted when new SMALL CELL LUNG CANCER EXTENSIVE STAGE trials appear
Sign up with your email to follow new studies for SMALL CELL LUNG CANCER EXTENSIVE STAGE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Triple-Drug attack shows promise against tough lung cancer
Disease control OngoingThis study tests a combination of two immunotherapy drugs (pembrolizumab and lenvatinib) plus standard chemotherapy in people with extensive-stage small cell lung cancer who have not had prior treatment. The goal is to see if this triple therapy is safe and can delay cancer growt…
Matched conditions: SMALL CELL LUNG CANCER EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated May 17, 2026 09:08 UTC
-
Lung cancer trial drops standard chemo drug, adds immunotherapy
Disease control OngoingThis study tests a new combination of chemotherapy (paclitaxel and carboplatin) plus an immunotherapy drug (durvalumab) for people with extensive-stage small cell lung cancer who haven't had treatment yet. The goal is to see if this combo works better than the usual treatment. Ab…
Matched conditions: SMALL CELL LUNG CANCER EXTENSIVE STAGE
Phase: PHASE2 • Sponsor: Intergroupe Francophone de Cancerologie Thoracique • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New combo therapy aims to extend control of aggressive lung cancer
Disease control OngoingThis early-phase trial tests whether adding chest radiation followed by immunotherapy drugs (durvalumab alone or with tremelimumab or olaparib) can help control extensive-stage small cell lung cancer after initial chemotherapy. About 25 adults whose cancer did not worsen after fi…
Matched conditions: SMALL CELL LUNG CANCER EXTENSIVE STAGE
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 13, 2026 16:03 UTC
-
Engineered immune cells take aim at tough lung cancer
Disease control OngoingThis early-stage trial tests a new treatment called LB2102, which uses a patient's own immune cells (T-cells) that have been modified to recognize and attack cancer cells that have a specific marker (DLL3). The study includes about 41 adults with advanced small cell lung cancer o…
Matched conditions: SMALL CELL LUNG CANCER EXTENSIVE STAGE
Phase: PHASE1 • Sponsor: Legend Biotech USA Inc • Aim: Disease control
Last updated May 04, 2026 16:31 UTC